EBV EBNA-LP Activators
EBV EBNA-LP, or Epstein-Barr Virus Nuclear Antigen Leader Protein, is an important early protein expressed by the Epstein-Barr Virus (EBV), a herpesvirus known for its role in various diseases including infectious mononucleosis and certain types of cancers such as Burkitt's lymphoma, Hodgkin's lymphoma, and nasopharyngeal carcinoma. EBNA-LP is crucial in the initial stages of EBV infection and plays a pivotal role in the transformation and immortalization of B lymphocytes, which is a key step in EBV's life cycle.
The protein functions primarily as a coactivator of EBNA2 (Epstein-Barr Virus Nuclear Antigen 2), enhancing its ability to activate the transcription of viral and specific cellular genes. This transcriptional activation is essential for the reprogramming of infected B cells into continuously proliferating, immortalized cells, which is a hallmark of EBV's latent infection. EBNA-LP, by assisting EBNA2, helps to establish and maintain this latent state, promoting the survival and proliferation of infected cells.EBNA-LP also interacts with other cellular and viral proteins and contributes to the alteration of the cellular environment to favor viral persistence and replication. Its expression is one of the earliest events following EBV infection of B cells and is a key factor in the switch from the virus's lytic cycle to its latent state.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
PGE2 | 363-24-6 | sc-201225 sc-201225C sc-201225A sc-201225B | 1 mg 5 mg 10 mg 50 mg | $57.00 $159.00 $275.00 $678.00 | 37 | |
PGE2 might influence immune response and could indirectly affect EBV activation and EBNA-LP expression. | ||||||
Butyric acid | 107-92-6 | sc-214640 sc-214640A | 1 kg 10 kg | $64.00 $177.00 | ||
Butyrate, as a histone deacetylase inhibitor, could potentially activate latent EBV, influencing EBNA-LP expression. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
PMA, a PKC activator, might induce lytic EBV replication, potentially increasing EBNA-LP expression. | ||||||
Sodium Butyrate | 156-54-7 | sc-202341 sc-202341B sc-202341A sc-202341C | 250 mg 5 g 25 g 500 g | $31.00 $47.00 $84.00 $222.00 | 19 | |
Sodium butyrate, affecting chromatin structure, could influence latent EBV activation and EBNA-LP expression. | ||||||
Hydroxyurea | 127-07-1 | sc-29061 sc-29061A | 5 g 25 g | $78.00 $260.00 | 18 | |
Hydroxyurea, inducing DNA replication stress, might affect viral replication and EBNA-LP expression. | ||||||
Cycloheximide | 66-81-9 | sc-3508B sc-3508 sc-3508A | 100 mg 1 g 5 g | $41.00 $84.00 $275.00 | 127 | |
Cycloheximide, inhibiting protein synthesis, could influence cellular and viral protein expression patterns, including EBNA-LP. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Bortezomib, a proteasome inhibitor, could affect cellular environment and indirectly influence viral protein expression. | ||||||
Valproic Acid | 99-66-1 | sc-213144 | 10 g | $87.00 | 9 | |
Valproic acid, as a histone deacetylase inhibitor, might impact latent EBV and thereby influence EBNA-LP expression. | ||||||
Retinoic Acid, all trans | 302-79-4 | sc-200898 sc-200898A sc-200898B sc-200898C | 500 mg 5 g 10 g 100 g | $66.00 $325.00 $587.00 $1018.00 | 28 | |
Retinoic acid, affecting cell differentiation, might indirectly impact EBV life cycle and EBNA-LP expression. | ||||||